Considering the importance and cost associated with oligonucleotide-based therapeutics, how can innovative computing imaging techniques be used to aid in the process, while also creating an audit trail and increasing the data derived from these experiments?

Since the completion of the human genome project in 2003, there has been huge growth in the utilisation of genomics, but how can partnerships in this area be used to improve patient experience

Synthetic biology has been a cornerstone in recent health advancements, including drug discovery, development and manufacturing, however there are challenges facing this market

The development and use of novel gene therapy approaches is increasing. With the advent of innovative technologies using improved tropism and safer viral-based systems, and nanotechnology advancing non-viral delivery of nucleic acid vectors, there will be more gene-based products entering the market in near future

Ipt talks with jacob tesdorpf at revvity about the recent developments in preclinical imaging, from ai-enchanced analysis to refined disease models

The World Health Organization (WHO) has recognised the scarcity of new antimicrobial agents in the clinical pipeline. The prevailing approach to combatting antimicrobial resistance cannot solely rely on developing new drugs. Instead, we must seek ways to better understand and more efficiently use the drugs already at our disposal.

IPT talks to Oliver Rinner of Biognosys about Bruker’s recent majority investment in the business and how this, along with its own developments, will affect the future of proteomics research

With its potential to transform various industries and fields of research − including pharmaceuticals, preventive healthcare, agriculture and food safety − metabolomics is a rapidly growing field that has the potential to revolutionise our understanding of biological systems and disease mechanisms

IPT talks to Tamsin Mansley of Optibrium about how AI has been used in drug discovery up until now, and how it can be best applied in the future

Non-human cells have been used in drug discovery for years. How are novel technologies helping researchers to move past this method?

What has led to the rising trend for Cell & Gene Therapy (CGT) developers to choose retroviral vectors over other potential vectors, and what are the many drivers behind this selection process?

IPT talks to Dr Fiona McLaughlin and Neil Bell of Avacta Therapeutics about the need for cohesion when researching and developing a new drug between life science companies, academia, and medical practitioners